Does ticlopidine cause neutropenia?
Ticlopidine (TCP) is a drug that inhibits platelet aggregation. Several studies have demonstrated its superiority over aspirin in preventing stroke and other thromboembolic diseases. However, neutropenia occurs in about 2% of TCP-treated patients, which therefore may advance to agranulocytosis, sepsis and death.
What can I monitor with ticlopidine?
Laboratory monitoring should include a complete blood count, with special attention to the absolute neutrophil count (WBC x % neutrophils), platelet count, and the appearance of the peripheral smear. Ticlopidine is occasionally associated with thrombocytopenia unrelated to TTP or aplastic anemia.
Why was ticlopidine discontinued?
Ticlopidine was approved for use in the United States in 1991, but it is currently rarely used, largely because of the risks of serious side effects including agranulocytosis, thrombotic thrombocytopenic purpura and aplastic anemia and the availability of clopidogrel, which has a similar mechanism of action and …
What are side effects of ticlopidine?
Common side effects of Ticlid include:
- diarrhea,
- stomach upset or pain,
- nausea,
- vomiting,
- dizziness,
- ringing in your ears, or.
- itching.
What is ticlopidine used for?
Ticlopidine is used to reduce the risk of stroke in people who have had a stroke or have had warning signs of a stroke and who cannot be treated with aspirin.
What type of drug is ticlopidine?
Ticlopidine works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It helps keep blood flowing smoothly in your body.
Is ticlopidine an antiplatelet?
Data synthesis: Ticlopidine is a new antiplatelet agent with a distinct mechanism of action. In the largest trial of the drug for the prevention of stroke, it was found to be more effective than aspirin in reducing the risk of stroke or death.
What drugs are similar to ticlopidine?
Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor….Ticlopidine.
| Clinical data | |
|---|---|
| PubChem CID | 5472 |
| IUPHAR/BPS | 7307 |
| DrugBank | DB00208 |
| ChemSpider | 5273 |
What should be avoided when taking ticlopidine hydrochloride?
You should not take ticlopidine if you have any active bleeding such as a stomach ulcer or bleeding in the brain (such as from a head injury), or a blood cell disorder such as anemia (lack of red blood cells) or low levels of platelets (cells that help your blood clot).
What is the mechanism of action of ticlopidine?
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.
What is ticlopidine hydrochloride used for?
How do you take ticlopidine?
How to use Ticlopidine 250 Mg Tablet
- Read the Patient Information Leaflet if available from your pharmacist before you start taking ticlopidine and each time you get a refill.
- Take this medication by mouth with food or just after a meal as directed by your doctor, usually twice daily.
When to discontinue ticlopidine after 3 months?
During the first 3 months of treatment, patients receiving Ticlopidine must, therefore, be hematologically and clinically monitored for evidence of neutropenia or TTP. If any such evidence is seen, Ticlopidine should be immediately discontinued.
How does ticlopidine affect the risk of stroke?
Ticlopidine significantly reduced the overall risk of stroke by 24% (p =.017) from 24.6 to 18.6 per 100 patients followed for 3 years, compared to placebo. During the first year the reduction in risk of fatal and nonfatal stroke over placebo was 33%.
When does aplastic anemia peak on ticlopidine?
The incidence of TTP peaks after about 3 to 4 weeks of therapy and neutropenia peaks at approximately 4 to 6 weeks. The incidence of aplastic anemia peaks after about 4 to 8 weeks of therapy.
How is ticlopidine used to treat stent thrombosis?
Ticlopidine was the first widely used thienopyridine for the prevention of stent thrombosis. Ticlopidine was approved for use by the FDA in patients undergoing PCI. It significantly lowers the risk of stent thrombosis in patients receiving BMSs at 30 days when given with aspirin.
